Karim Arafah, Mark Kriegsmann, Marcus Renner, Felix Lasitschka, Margaux Fresnais, Katharina Kriegsmann, Moritz von Winterfeld, Benjamin Goeppert, Jörg Kriegsmann, Rita Casadonte, Daniel Kazdal, Philippe Bulet, Rémi Longuespée
Journal: Proteomics. Clinical applications 2021;14(4):e1900110
PMID: 32003543
PURPOSE
Differential diagnosis of ulcerative colitis (UC) and Crohn's disease (CD) is of utmost importance for the decision making of respective therapeutic treatment strategies but in about 10-15% of cases, a clinical and histopathological assessment does not lead to a definite diagnosis. The aim of the study is to characterize proteomic differences between UC and CD.
EXPERIMENTAL DESIGN
Microproteomics is performed on formalin-fixed paraffin-embedded colonic tissue specimens from 9 UC and 9 CD patients. Protein validation is performed using immunohistochemistry (IHC) (n =51, n =62, n =10) followed by digital analysis.
RESULTS
Microproteomic analyses reveal eight proteins with higher abundance in CD compared to UC including proteins related to neutrophil activity and damage-associated molecular patterns. Moreover, one protein, Aldo-keto reductase family 1 member C3 (AKR1C3), is present in eight out of nine CD and absent in all UC samples. Digital IHC analysis reveal a higher percentage and an increased expression intensity of AKR1C3-positive epithelial cells in CD compared to UC and in controls compared to inflammatory bowel disease (IBD).
CONCLUSION AND CLINICAL RELEVANCE
Overall, the results suggest that microproteomics is an adequate tool to highlight protein patterns in IBD. IHC and digital pathology might support future differential diagnosis of UC and CD.
© 2020 The Authors. Proteomics - Clinical Applications published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Medical:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.